TY -的T1 -公开分类drugs: a new proposal based on the most recent evidence JF - European Respiratory Journal JO - Eur Respir J SP - 887 LP - 893 DO - 10.1183/13993003.00432-2015 VL - 46 IS - 4 AU - Caminero, Jose A. AU - Scardigli, Anna Y1 - 2015/10/01 UR - //www.qdcxjkg.com/content/46/4/887.abstract N2 - Multidrug-resistant (MDR) tuberculosis (TB) (resistance to at least isoniazid and rifampicin), with >480 000 cases in 2013, 10% of them being affected by extensively drug-resistant (XDR)-TB (MDR-TB with additional resistance to any fluoroquinolone, and to injectable second-line drugs (SLDs) (capreomycin, kanamycin or amikacin)), continues to represent a real threat to TB control [1–4]. In some high MDR-TB burden countries, the prevalence of MDR-TB among new cases exceeds 20% and among retreatment cases, reaches almost 50% [1, 5].The classification of the anti-TB drugs should probably be modified to optimise the use old and new compounds http://ow.ly/QbDSPThe authors wish to thank R. Centis and L. D'Ambrosio (WHO Collaborating Centre for TB and Lung Disease, Tradate, Italy) for their editorial and technical support. The authors alone are responsible for the views expressed in this publication and they do not necessarily represent the decisions or policies of their institutions. ER -